Compare RVYL & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVYL | ALBT |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 8.4M |
| IPO Year | N/A | N/A |
| Metric | RVYL | ALBT |
|---|---|---|
| Price | $0.34 | $1.42 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.5M | 37.6K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,858,000.00 | $1,611,940.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $297.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 29.50 | N/A |
| 52 Week Low | $0.25 | $1.21 |
| 52 Week High | $2.33 | $11.66 |
| Indicator | RVYL | ALBT |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 34.92 |
| Support Level | $0.32 | $1.22 |
| Resistance Level | $0.37 | $1.76 |
| Average True Range (ATR) | 0.04 | 0.16 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 66.35 | 29.88 |
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.